DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 12/26/2019 --Lyme Disease Market Insights, Epidemiology and Market Forecast-2027

(Albany, US) DelveInsight launched a new report on Lyme Disease Market Insights, Epidemiology and Market Forecast-2028

Some of the key facts of the report

1. Total Lyme Disease incident population in the seven major markets was 492,398 in 2017.
2. The gender-specific Lyme Disease incident population was found to be 170,644 males and 161,348 females in 2017 that will increase by 2028 for the study period 2017–2028.
3. Japan had 82 diagnosed incident cases of Lyme disease in 2017.

Key benefits of the report

1. Lyme Disease market report covers a descriptive overview and comprehensive insight of the Lyme Disease epidemiology and Lyme Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Lyme Disease market report provides insights on the current and emerging therapies.
3. Lyme Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Lyme Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Lyme Disease market.

Request for sample pages

"The US and the European 5 Countries account for approximately 67% and 33% of the total Incident cases out of all the Lyme disease cases in 7 major markets in 2017."

Lyme disease treatment course covers Antibiotics comprising Tetracycline (Doxycycline), Penicillins (Amoxicillin and Benzathine Penicillin), Cephalosporins (Cefuroxime, Ceftriaxone and Cefotaxime), Macrolides (Azithromycin and Clarithromycin). The patient has to undergo the Second-Line Treatment if the first-line treatment does not benefit the individual. The second line of therapy includes Marcrolide Antibiotics (Azithromycin and Clarithromycin). Macrolide Antibiotics are used for individuals who cannot tolerate the other antibiotics or the first line of treatment. Azithromycin and Clarithromycin are macrolide antibiotics that are used in humans for Lyme disease treatment. Both the products have shown better tolerability than the older antibiotic Erythromycin in having fewer gastrointestinal side effects.

The total Lyme disease market size is calculated by including the market size for Acute Lyme disease, Chronic Lyme disease and Emerging Therapy separately. The full Lyme disease market size (pharmacological market) was USD 408.35 million in 2017. The Lyme disease market is expected to show positive growth, mainly attributed to increased diagnosed incidence and also, the launch of upcoming therapy during the forecast period. The United States accounts for the largest market size of Lyme Disease in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

The launch of the emerging therapies is expected to significantly impact Lyme Disease treatment scenario in the upcoming years:-
Drugs covered
1. VLA15
And many others

The key players in Lyme Disease market are:
1. Valneva
And many others

Table of contents

1. Key Insights
2. Lyme Disease Market Overview at a Glance
3. Lyme Disease Disease Background and Overview
4. Lyme Disease Epidemiology and Patient Population
5. 7MM
6. Country Wise Lyme Disease Epidemiology
6.1. United States
6.2. EU5 Countries
6.3. Germany
6.4. France
6.5. Italy
6.6. Spain
6.7. United Kingdom
6.8. Japan
7. Lyme Disease Treatments & Medical Practices
8. Prophylactic Practices
9. Lyme Disease Emerging Drugs
9.1. Key Cross Competition
9.2. VLA15: Valneva
10. Lyme Disease 7 Major Market Analysis
11. The United States Market Outlook
12. EU-5 Countries: Market Outlook
12.1.Germany
12.2. France
12.3. Italy
12.4. Spain
12.5.United Kingdom
13. Japan: Market Outlook
13.1.Japan Market Size
14. Market Drivers
15. Market Barriers
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.